#### National specimen packaging and transportation guidelines: practical considerations

Natacha Milhano leng Vanra WHO 1<sup>st</sup> November 2018 Kampong Cham

#### Questionnaire

- 1. Is there a focal person in your laboratory responsible for laboratory issues and interfacing with the MoH?
- 2. Is there a focal person at each laboratory that is responsible for the specimen referral system?
- 3. What types of transport are used for sample transportation from/to your laboratory? Car (private, company rental), motorbike, taxi etc? Is there a schedule- once, twice, more often a week- or as required?
- 4. Do you have sample transportation SOP in your laboratory?
- 5. Are clinical and laboratory staff trained in SOPs for sample collection, referral, packaging, transportation and reception?
- 6. Are couriers trained in SOPs, biosafety, biosecurity, spill clean-up, etc.?
- 7. Are request forms standardized for all testing and being used at all levels?
- 8. Are standardized transportation logs and chain of custody forms available and used by anyone transporting specimens?
- 9. Is triple packaging used for all national and international sample transportation?
- 10. Is there a system in place that allows for a sample to be tracked from the submitting laboratory to the testing laboratory? What is the system?
- 11. How are results of laboratory tests delivered? Paper, SMS printer, electronically, etc.?
- 12. If your laboratory has an electronic system, is it CamLIS or another? Please specify.
- 13. Does your laboratory receive referred samples? If so, list which laboratories refer which types of specimens for which tests.
- 14. Does your laboratory refer samples to another laboratory? If so, list which types of specimens are referred to which laboratories for which tests.
- 15. How many samples do you receive per week, on average, in your lab? Of these, how many, on average, are referred from other labs?
- 16. How many samples do you refer, per week, from your lab?
- 17. How do facilities and laboratories communicate about specimen quality, rejections, missing results, etc.?

#### **Questionnaire results**



## National specimen packaging guidelines

#### Contents

1. Introduction

2. Definitions : Infectious substances, Diagnostic specimens, Cultures, Biological products, Genetically modified organisms, Medical or clinical wastes, Exemptions

3. Preparations for shipment: Standard precautions, Transport planning (shipper, carrier and receiver considerations), Specimen storage, Other considerations

- 4. Packaging, labelling and documentation: General triple package system, Category A shipping, Category B shipping
- 5. Refrigerants
- 6. Overpacks
- 7. Reuse of packaging materials
- 8. Training
- 9. Transportation of specimens
- 10. Specimen rejection
- 11. Spill clean-up procedure

Annexes: List of UN category A pathogens, Specimen storage conditions, Packing Instruction P620, Packing Instruction P650, Packing Instruction P904, Flowchart for classification of infectious substances and diagnostic specimens, Specimen request form

#### Specimen referral system set-up



Increasing level of testing complexity

### **Practical considerations**

1)Planning 2)Human resources 3)Training 4) Supply chain 5)System for transport 6) Monitoring and evaluation 7)Partnership 8)Communication

# Planning

- Strong leadership from MoH
- Operational cost
- Mapping of referral sites to testing labs (CamLIS)
- Flexibility for integration, adaptation to innovative technologies and unforseen outbreaks
- Development and dissemination of tools (guidelines and SOPs, prakas?)

#### Human resources

Identify who involved with packaging, transportation, and reception of specimens: clinicians/nurses, lab staff, hospital drivers, RRTs, community healthcare workers,.....

# Training

- Target audience: all relevant staff handling specimens
- Training curricula, guidelines, SOPs, ...
- Documentation of requisition forms and transport logs

#### **BIOSAFETY!!!**

# Supply chain

- Procurement of standard transportation containers, packaging materials, and storage materials
- PPE
- Spill kits
- CamLIS with tracking system?

# System for transport

Identify reliable transport system: hospital drivers, transportation company?

### Monitoring and evaluation

- Establish indicators for monitoring specimens (transport time, specimen rejection rate, number of patients seen, etc)
- Assess impact on capacity building and sustainability

# Partnership

Engage stakeholders for increased uptake, coverage, implementation, and monitoring and evaluation (include private partnerships at a later stage?)

## Communication

- Maintain communication between referring sites and testing site(s) to resolve any problems that are identified
- Maintain communication strategies for sharing best practices, opportunities, and challenges



#### Decentralized versus Centralized



CID 2017:64 (15 March)

### **Centralized systems**

Advantages	Disadvantages
<ul> <li>Easy to manage samples to referral lates and sample loss of stealing</li> <li>Arriving with schedule</li> </ul>	<ul> <li>Need space/place</li> <li>Need staff on duty</li> <li>May be more expensive</li> <li>Double work</li> <li>Limitation of coverage, lack of participation from sites</li> </ul>

#### **Decentralized systems**

	Advantages	Disadvantages
•	No double work	Limitation of quality data
•	Faster	management
•	More affordable	
•	No need for extra staff	
•	Participation from sites	
•	No need for	
	intrainstitutional	
	specimen tranfer!	

#### **Centralized models**

Country/ Programme	Interventions	Outcomes
Uganda HIV, TB, malaria, West Nile virus, Zika virus, Crimean- Congo hemorrhagic fever virus	<ul> <li>Mapping of hub-and-spoke transport system</li> <li>Training of bike riders</li> </ul>	<ul> <li>Increased access to EID testing with increased volumes by 36.4% and 51.7% per month in Jinja and Kampala, respectively</li> <li>Turnaround time (TAT) reduced from 1–2 mo to 5–10 d for EID results</li> <li>TAT reduced from 21 d to 3 d for TB results</li> <li>Overall operational cost reduced by 62% (from US\$6460 to US\$2428) and projected to save US\$1.2 million over 4 y</li> <li>Flexible for integrated specimens: EID, CD4, chemistry, hematology, TB, and malaria smear referral</li> </ul>
HIV, H1N1 influenza	<ul> <li>Planning linking of Caribbean countries to regional reference</li> <li>laboratory in Barbados</li> <li>Development of SOPs and provision of standard materials for packaging and transportation</li> </ul>	<ul> <li>Enabled initiation of HIV patients on ART treatment</li> <li>Ability to test for H1N1</li> </ul>

#### **Decentralized models**

Country/	Interventions	Outcomes
Programme		
Vietnam TB	<ul> <li>Development of SOPs for safe packaging of specimens</li> <li>Training of facility staff on use of SOPs</li> <li>Identification and hiring of courier service and transition to postal service</li> <li>Provision of standard packaging materials for specimens</li> </ul>	<ul> <li>Number of TB specimens examined increased by 30% (from 21 870 to 28 413) and 46% (from 17 160 to 25 097) in Hanoi and Ho Chi Minh city, respectively</li> <li>Number of new patients starting MDR-TB treatment increased by 19% (from 578 to 713)</li> <li>Specimen delivery time from 3 wk to 1 wk</li> <li>Improved safety of referral system</li> </ul>
Haiti HIV	<ul> <li>Establishment of logistic and coordination committee</li> <li>Mapping of hub-and-spoke transport system for facilities</li> <li>Improvement of infrastructure at hub and laboratory</li> <li>Training different cadres (laboratory technicians, drivers)</li> <li>Development of SOPs and provision of standard packaging materials</li> </ul>	<ul> <li>Increased access to quality CD4 testing from 27 sites to 113 sites (315%)</li> <li>Testing volumes for CD4 increased by 76%</li> <li>Number of patients enrolled on ART for new sites joining the specimen</li> <li>referral network increased by 182% within 6 mo</li> </ul>

# Evaluation of performance of specimen referral system

- What is the proportion of specimen collection sites participating in the current specimen referral system?
- What is average turnaround time from collection to pick-up?
- What is average turnaround time from pick-up to delivery to the testing laboratory?
- What is average turnaround time from obtaining a result to delivery of the results to the referring laboratory or clinician?

#### **Pilot timeline**



# Group activity: setting up a pilot specimen transportation system

#### 1) ILI/SARI

- 2) Outbreak (most affected provinces?)
- 3) Other surveillance systems? Japanese encephalitis, dengue, malaria...

Points to consider: how many sites are involved? How do they usually transport specimens? Are the transporters trained?

- 1. Planning
- 2. Human resources
- 3. Training
- 4. Supply chain
- 5. System for transport
- 6. Monitoring and evaluation
- 7. Partnership
- 8. Communication

# Thank you!!